Outcome in three siblings with antibody-mediated transient congenital hypothyroidism

Pacaud, Danièle; Huot, Céline; Gattereau, A; Brown, Rosalind S.; Glorieux, Jacqueline; Dussault, Jean H.; Vliet, Guy Van

doi:10.1016/s0022-3476(95)70308-x

Cited by 30 publications

(18 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seen in approximately 1:180,000 newborns, this diagnosis should be considered if more than one infant from the same mother has CH. Transient CH due to TRBAbs can last up to 3 to 6 months from birth as maternal antibody levels drop (19)(20)(21).…”

Section: Thyrotropin Receptor Blocking Antibodies (Trbabs)mentioning

confidence: 99%

Transient hypothyroidism in the newborn: to treat or not to treat

Kanike¹,

Davis²,

Shekhawat³

2017

Transl. Pediatr

View full text Add to dashboard Cite

show abstract

Section: Thyrotropin Receptor Blocking Antibodies (Trbabs)mentioning

confidence: 99%

Transient hypothyroidism in the newborn: to treat or not to treat

Kanike¹,

Davis²,

Shekhawat³

2017

Transl. Pediatr

View full text Add to dashboard Cite

show abstract

“…Transfer of thyroid hormones of maternal or even placental origin may largely protect the developing brain of the fetus, contrasting with the severe brain damage occurring in infants born to severely hyperthyroxinémie mothers resulting from severe iodine deficiency [86][87][88], autoimmune thyroiditis [89,90], or fetomaternal Pit-1 deficiency [91].…”

Section: Treatment and Prognosis O F Permanent Sporadic Chmentioning

confidence: 99%

Neonatal Screening for Congenital Hypothyroidism Results and Perspectives

Delange¹

1997

Horm Res

201

110

View full text Add to dashboard Cite

Systematic screening for congenital hypothyroidism in the neonate constitutes a major progress in the prevention of mental retardation, as the condition occurs in 1/4,000 newborns and necessarily results in brain damage if not properly detected and treated during the first days of life. Screening and diagnostic and therapeutic procedures are discussed, as well as outcome and prognosis of the affected infants. Primary thyroid-stimulating hormone screening is almost universally recommended. Early therapy (within 14 days) with appropriate doses of thyroxine (about 10 µg/kg/day) will prevent any brain damage even in case of evidence of fetal hypothyroidism, as thyroxine of maternal origin will reach the fetus and largely protect him. Neonatal thyroid screening is also a particularly sensitive monitoring tool in the evaluation of the effects and of the correction of iodine deficiency at the population level.

show abstract

“…Consequently, fetal hyperthyroidism develops during the second half of gestation, typically in fetuses born to women with high levels of thyroid-stimulating immunoglobulins. However, TSH-receptor-blocking antibodies also might be present in pregnant women with Graves’ disease or in the rare cases in which mothers have hypothyroidism caused by TSH-blocking antibodies [19,20]. The transplacental passage of these antibodies has been demonstrated, and the clinical symptoms in the fetus are the result of the imbalance between the stimulating action of the thyroid-stimulating immunoglobulins and the inhibitory action of the TSH receptor-blocking antibodies.…”

Section: Fetal Hyperthyroidismmentioning

confidence: 99%

Thyroid Disorders during Pregnancy: Impact on the Fetus

Polak

2011

Horm Res Paediatr

View full text Add to dashboard Cite

Background: Advances in prenatal imaging techniques and in fetal hormonology now allow for identification of disorders of thyroid function in the fetus. These can potentially be treated in utero by giving drugs to the mother. Aims: This review examines the feasibility of in utero treatment of fetal thyroid disorders, either indirectly by treating the mother or by giving the necessary drugs directly to the fetus. Methodologies: In women with Graves’ disease, autoimmune fetal hyperthyroidism can generally be treated in a noninvasive way by optimizing treatment of the mother, such as by increasing the dose of antithyroid drugs. For goitrous fetal hypothyroidism leading to hydramnios, repeated intra-amniotic injections of thyroxine have been reported to decrease the size of the fetal thyroid. Results: Experience with such procedures is limited but positive. The risk that direct in utero treatment of the fetus may provoke premature labor or cause infection should be carefully evaluated. Conclusions: Follow-up of the efficacy and the possible long-term consequences of medical interventions to normalize thyroid function of the fetus are of great importance. Specialized care of the fetus should be provided by skilled teams with extensive experience in prenatal care.

show abstract

Outcome in three siblings with antibody-mediated transient congenital hypothyroidism

Cited by 30 publications

References 12 publications

Transient hypothyroidism in the newborn: to treat or not to treat

Transient hypothyroidism in the newborn: to treat or not to treat

Neonatal Screening for Congenital Hypothyroidism Results and Perspectives

Thyroid Disorders during Pregnancy: Impact on the Fetus

Contact Info

Product

Resources

About